Press release
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that
About this update from Incyte Corporation
[{"type":"text","content":" WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31); and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14).\n\n\n“We are pleased to have virtual platforms such as ASCO20 and EHA25 to continue sharing important data with the scientific community in a timely manner,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “These data demonstrate the strength of our broad oncology portfolio and our partnerships; and reinforce our commitment to finding solutions that can help meet patients’ needs.”\n\n\nKey abstracts accepted by ASCO and EHA include:\n\n\nASCO Abstracts\n\n\nOral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, May 29, 2020, 8:00 AM ET.\n\n\nOral Presentations\n\n\nCapmatinib in Patients with High-Level MET-Amplified Advanced Non-Small Cell Lung Cancer (NSCLC): Results from the Phase 2 GEOMETRY mono-1 Study (Abstract #9509, Session: MET Mutations: The Meat of the Matter)1\n\n\nInterim Analysis (IA) of OPTIC: A Dose-Ranging Study of Three Ponatinib (PON) Starting Doses (Abstract #7502, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2\n\n\nE-Poster Presentations \n\n\nAn Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase 2 PACE Trial (NCT01207440) in Patients (pts) with Ph+ Leukemia (Abstract #7550, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2\n\n\nRe-MIND Study: A Propensity Score-Based 1:1 Matched Comparison of Tafasitamab + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #8020, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia)3\n\n\nSafety and Efficacy of Pemigatinib Plus Pembrolizumab Combination Therapy in Patients (pts) with Advanced Malignancies: Results from FIGH...